# Special Issue

# Personalized Diagnosis, Treatment, and Prognosis of Parkinson's Disease

# Message from the Guest Editors

Although effective treatments for the symptom control of Parkinson's disease (PD) have been developed in the past 20 years, it remains a clinical diagnosis based on motor and nonmotor signs and symptoms. Our understanding of the pathophysiology, phenotypic diversity, and progression of Parkinson's disease remains unsatisfactory. This Special Issue "Personalized" Diagnosis, Treatment, and Prognosis of Parkinson's Disease" aims to highlight the current state of science and showcase some of the latest findings in the field of PD. We invite researchers in this field to submit original research and review articles, including studies on the discovery of novel biomarkers and new targets for therapeutic interventions to pave the path towards developing personalized medicine to achieve optimal health and wellness in PD.

### **Guest Editors**

# Dr. Cheng-Hsien Lu

Department of Neurology, Chang Gung Memorial Hospital-Kaohsiung and Chang Gung University, 123, Ta-Pei Road, Niao Sung district, Kaohsiung City 83304, Taiwan

#### Dr. Wei-Che Lin

Department of Diagnostic Radiology, Chang Gung Memorial Hospital-Kaohsiung and Chang Gung University, 123, Ta-Pei Road, Niao Sung District, Kaohsiung City 83304, Taiwan

### Deadline for manuscript submissions

closed (31 October 2022)



# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



### mdpi.com/si/101240

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm





# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



# About the Journal

# Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

### **Editor-in-Chief**

### Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

### **Author Benefits**

### **High Visibility:**

indexed within Scopus, PubMed, PMC, Embase, and other databases.

### **Journal Rank:**

CiteScore - Q1 (Medicine (miscellaneous))

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

